ID   GRB14_HUMAN             Reviewed;         540 AA.
AC   Q14449; B7Z7F9; Q7Z6I1;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   15-FEB-2005, sequence version 2.
DT   22-JUL-2015, entry version 139.
DE   RecName: Full=Growth factor receptor-bound protein 14;
DE   AltName: Full=GRB14 adapter protein;
GN   Name=GRB14;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ILE-90.
RX   PubMed=8647858; DOI=10.1074/jbc.271.21.12502;
RA   Daly R.J., Sanderson G.M., Janes P.W., Sutherland R.L.;
RT   "Cloning and characterization of GRB14, a novel member of the GRB7
RT   gene family.";
RL   J. Biol. Chem. 271:12502-12510(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   INTERACTION WITH INSR.
RX   PubMed=11726652; DOI=10.1074/jbc.M106574200;
RA   Bereziat V., Kasus-Jacobi A., Perdereau D., Cariou B., Girard J.,
RA   Burnol A.F.;
RT   "Inhibition of insulin receptor catalytic activity by the molecular
RT   adapter Grb14.";
RL   J. Biol. Chem. 277:4845-4852(2002).
RN   [7]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PDPK1.
RX   PubMed=15210700; DOI=10.1074/jbc.M405340200;
RA   King C.C., Newton A.C.;
RT   "The adaptor protein Grb14 regulates the localization of 3-
RT   phosphoinositide-dependent kinase-1.";
RL   J. Biol. Chem. 279:37518-37527(2004).
RN   [8]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT THR-2, IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS], AND CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [9]
RP   FUNCTION, INTERACTION WITH NRAS, PHOSPHOINOSITIDE-BINDING, SUBCELLULAR
RP   LOCATION, DOMAIN PH, AND MUTAGENESIS OF LYS-140; GLU-245; GLN-246;
RP   LYS-252; GLY-299; GLN-348 AND ASN-349.
RX   PubMed=19648926; DOI=10.1038/nsmb.1642;
RA   Depetris R.S., Wu J., Hubbard S.R.;
RT   "Structural and functional studies of the Ras-associating and
RT   pleckstrin-homology domains of Grb10 and Grb14.";
RL   Nat. Struct. Mol. Biol. 16:833-839(2009).
RN   [10]
RP   ERRATUM.
RA   Depetris R.S., Wu J., Hubbard S.R.;
RL   Nat. Struct. Mol. Biol. 16:1331-1331(2009).
RN   [11]
RP   INTERACTION WITH TEK/TIE2, AND PHOSPHORYLATION.
RX   PubMed=20973951; DOI=10.1186/1478-811X-8-30;
RA   Sturk C., Dumont D.J.;
RT   "Tyrosine phosphorylation of Grb14 by Tie2.";
RL   Cell Commun. Signal. 8:30-30(2010).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-9 (ISOFORM 2), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 361-419 AND 433-537 IN
RP   COMPLEX WITH INSR.
RX   PubMed=16246733; DOI=10.1016/j.molcel.2005.09.001;
RA   Depetris R.S., Hu J., Gimpelevich I., Holt L.J., Daly R.J.,
RA   Hubbard S.R.;
RT   "Structural basis for inhibition of the insulin receptor by the
RT   adaptor protein Grb14.";
RL   Mol. Cell 20:325-333(2005).
RN   [14]
RP   VARIANTS ILE-90 AND TYR-507.
RX   PubMed=21220648; DOI=10.1001/archneurol.2010.351;
RA   Daoud H., Valdmanis P.N., Gros-Louis F., Belzil V., Spiegelman D.,
RA   Henrion E., Diallo O., Desjarlais A., Gauthier J., Camu W., Dion P.A.,
RA   Rouleau G.A.;
RT   "Resequencing of 29 candidate genes in patients with familial and
RT   sporadic amyotrophic lateral sclerosis.";
RL   Arch. Neurol. 68:587-593(2011).
CC   -!- FUNCTION: Adapter protein which modulates coupling of cell surface
CC       receptor kinases with specific signaling pathways. Binds to, and
CC       suppresses signals from, the activated insulin receptor (INSR).
CC       Potent inhibitor of insulin-stimulated MAPK3 phosphorylation.
CC       Plays a critical role regulating PDPK1 membrane translocation in
CC       response to insulin stimulation and serves as an adapter protein
CC       to recruit PDPK1 to activated insulin receptor, thus promoting
CC       PKB/AKT1 phosphorylation and transduction of the insulin signal.
CC       {ECO:0000269|PubMed:15210700, ECO:0000269|PubMed:19648926}.
CC   -!- SUBUNIT: Interacts with the cytoplasmic domain of the
CC       autophosphorylated insulin receptor (INSR), through the SH2 domain
CC       (By similarity). Interacts with GRB14 (via BPS domain); this
CC       interaction protects the tyrosines in the activation loop on INSR
CC       from dephosphorylation. Binds to the ankyrin repeat region of
CC       TNKS2 via its N-terminus. Interacts with activated NRAS. Interacts
CC       (via SH2 domain) with TEK/TIE2 (tyrosine phosphorylated).
CC       {ECO:0000250, ECO:0000269|PubMed:11726652,
CC       ECO:0000269|PubMed:15210700, ECO:0000269|PubMed:16246733,
CC       ECO:0000269|PubMed:19648926, ECO:0000269|PubMed:20973951}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Golgi apparatus membrane;
CC       Peripheral membrane protein. Endosome membrane; Peripheral
CC       membrane protein. Note=Upon insulin stimulation, translocates to
CC       the plasma membrane.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q14449-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q14449-2; Sequence=VSP_056582, VSP_056583;
CC         Note=No experimental confirmation available. Contains a
CC         phosphothreonine at position 9. {ECO:0000269|PubMed:24275569};
CC   -!- TISSUE SPECIFICITY: Expressed at high levels in the liver, kidney,
CC       pancreas, testis, ovary, heart and skeletal muscle.
CC   -!- DOMAIN: The PH domain binds relatively non-specifically and with
CC       low affinity to several phosphoinositides, the best binder being
CC       PI(3,4,5)P3. {ECO:0000269|PubMed:19648926}.
CC   -!- PTM: Phosphorylated on serine residues. Phosphorylated on tyrosine
CC       residues by TEK/TIE2. {ECO:0000269|PubMed:20973951}.
CC   -!- SIMILARITY: Belongs to the GRB7/10/14 family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 PH domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00145}.
CC   -!- SIMILARITY: Contains 1 Ras-associating domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00166}.
CC   -!- SIMILARITY: Contains 1 SH2 domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00191}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L76687; AAC15861.1; -; mRNA.
DR   EMBL; AK301961; BAH13595.1; -; mRNA.
DR   EMBL; AC107075; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC110086; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471058; EAX11342.1; -; Genomic_DNA.
DR   EMBL; BC053559; AAH53559.1; -; mRNA.
DR   CCDS; CCDS2222.1; -. [Q14449-1]
DR   RefSeq; NP_001290351.1; NM_001303422.1. [Q14449-2]
DR   RefSeq; NP_004481.2; NM_004490.2. [Q14449-1]
DR   UniGene; Hs.411881; -.
DR   PDB; 2AUG; X-ray; 2.30 A; A/B=433-537.
DR   PDB; 2AUH; X-ray; 3.20 A; B=361-419.
DR   PDB; 4K81; X-ray; 2.40 A; A/C/E/G=106-356.
DR   PDBsum; 2AUG; -.
DR   PDBsum; 2AUH; -.
DR   PDBsum; 4K81; -.
DR   DisProt; DP00230; -.
DR   ProteinModelPortal; Q14449; -.
DR   SMR; Q14449; 106-356, 373-537.
DR   BioGrid; 109145; 10.
DR   DIP; DIP-42605N; -.
DR   IntAct; Q14449; 10.
DR   MINT; MINT-1894128; -.
DR   STRING; 9606.ENSP00000263915; -.
DR   PhosphoSite; Q14449; -.
DR   BioMuta; GRB14; -.
DR   DMDM; 59802920; -.
DR   MaxQB; Q14449; -.
DR   PaxDb; Q14449; -.
DR   PRIDE; Q14449; -.
DR   DNASU; 2888; -.
DR   Ensembl; ENST00000263915; ENSP00000263915; ENSG00000115290.
DR   GeneID; 2888; -.
DR   KEGG; hsa:2888; -.
DR   UCSC; uc002ucl.3; human. [Q14449-1]
DR   UCSC; uc010zcv.2; human.
DR   CTD; 2888; -.
DR   GeneCards; GC02M165350; -.
DR   HGNC; HGNC:4565; GRB14.
DR   HPA; CAB022294; -.
DR   HPA; HPA035052; -.
DR   HPA; HPA035053; -.
DR   MIM; 601524; gene.
DR   neXtProt; NX_Q14449; -.
DR   PharmGKB; PA28961; -.
DR   eggNOG; NOG307156; -.
DR   GeneTree; ENSGT00550000074537; -.
DR   HOGENOM; HOG000231904; -.
DR   HOVERGEN; HBG000468; -.
DR   InParanoid; Q14449; -.
DR   OMA; ERIIEDH; -.
DR   OrthoDB; EOG7SFHW7; -.
DR   PhylomeDB; Q14449; -.
DR   TreeFam; TF317511; -.
DR   Reactome; REACT_12621; Tie2 Signaling.
DR   SignaLink; Q14449; -.
DR   ChiTaRS; GRB14; human.
DR   EvolutionaryTrace; Q14449; -.
DR   GeneWiki; GRB14; -.
DR   GenomeRNAi; 2888; -.
DR   NextBio; 11411; -.
DR   PRO; PR:Q14449; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; Q14449; -.
DR   CleanEx; HS_GRB14; -.
DR   ExpressionAtlas; Q14449; baseline and differential.
DR   Genevisible; Q14449; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0010008; C:endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005070; F:SH3/SH2 adaptor activity; TAS:ProtInc.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   Gene3D; 2.30.29.30; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR015042; BPS-dom.
DR   InterPro; IPR011993; PH-like_dom.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR000159; Ras-assoc.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR029071; Ubiquitin-rel_dom.
DR   Pfam; PF08947; BPS; 1.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF00788; RA; 1.
DR   Pfam; PF00017; SH2; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00314; RA; 1.
DR   SMART; SM00252; SH2; 1.
DR   SUPFAM; SSF54236; SSF54236; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS50200; RA; 1.
DR   PROSITE; PS50001; SH2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   Cytoplasm; Endosome; Golgi apparatus; Membrane; Phosphoprotein;
KW   Polymorphism; Reference proteome; SH2 domain.
FT   INIT_MET      1      1       Removed. {ECO:0000269|PubMed:19413330}.
FT   CHAIN         2    540       Growth factor receptor-bound protein 14.
FT                                /FTId=PRO_0000150348.
FT   DOMAIN      106    192       Ras-associating. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00166}.
FT   DOMAIN      234    342       PH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00145}.
FT   DOMAIN      439    535       SH2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   MOD_RES       2      2       N-acetylthreonine.
FT                                {ECO:0000269|PubMed:19413330}.
FT   VAR_SEQ       1     21       MTTSLQDGQSAASRAAARDSP -> MSLSARRVTLPAITPI
FT                                ILQKR (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_056582.
FT   VAR_SEQ      22    108       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_056583.
FT   VARIANT      90     90       F -> I (in dbSNP:rs61748245).
FT                                {ECO:0000269|PubMed:21220648,
FT                                ECO:0000269|PubMed:8647858}.
FT                                /FTId=VAR_065758.
FT   VARIANT     507    507       H -> Y (in a patient with amyotrophic
FT                                lateral sclerosis).
FT                                {ECO:0000269|PubMed:21220648}.
FT                                /FTId=VAR_065759.
FT   MUTAGEN     140    140       K->A: Partial loss of INSR-binding. Loss
FT                                of inhibition of AKT1 activation. Loss of
FT                                inhibition of MAPK3 phosphorylation. Loss
FT                                of NRAS-binding.
FT                                {ECO:0000269|PubMed:19648926}.
FT   MUTAGEN     245    245       E->G: 4-fold increase in PI(3,4,5)P3-
FT                                binding affinity; when associated with S-
FT                                246. {ECO:0000269|PubMed:19648926}.
FT   MUTAGEN     246    246       Q->S: 4-fold increase in PI(3,4,5)P3-
FT                                binding affinity; when associated with G-
FT                                245. {ECO:0000269|PubMed:19648926}.
FT   MUTAGEN     252    252       K->A: Partial loss of INSR-binding. Loss
FT                                of inhibition of AKT1 activation. Loss of
FT                                inhibition of MAPK3 phosphorylation. Loss
FT                                of translocation to the plasma membrane
FT                                upon insulin-stimulation. More than 3-
FT                                fold decrease in PI(3,4,5)P3-binding
FT                                affinity. {ECO:0000269|PubMed:19648926}.
FT   MUTAGEN     299    299       G->N: No effect on PI(3,4,5)P3-binding.
FT                                {ECO:0000269|PubMed:19648926}.
FT   MUTAGEN     348    348       Q->A: Loss of inhibition of AKT1
FT                                activation; when associated with A-349.
FT                                Loss of inhibition of MAPK3
FT                                phosphorylation; when associated with A-
FT                                349. No effect on INSR-binding; when
FT                                associated with A-349.
FT                                {ECO:0000269|PubMed:19648926}.
FT   MUTAGEN     349    349       N->A: Loss of inhibition of AKT1
FT                                activation; when associated with A-348.
FT                                Loss of inhibition of MAPK3
FT                                phosphorylation; when associated with A-
FT                                348. No effect on INSR-binding; when
FT                                associated with A-348.
FT                                {ECO:0000269|PubMed:19648926}.
FT   STRAND      107    113       {ECO:0000244|PDB:4K81}.
FT   STRAND      119    125       {ECO:0000244|PDB:4K81}.
FT   HELIX       130    141       {ECO:0000244|PDB:4K81}.
FT   STRAND      149    155       {ECO:0000244|PDB:4K81}.
FT   TURN        156    159       {ECO:0000244|PDB:4K81}.
FT   STRAND      160    163       {ECO:0000244|PDB:4K81}.
FT   HELIX       170    175       {ECO:0000244|PDB:4K81}.
FT   STRAND      184    189       {ECO:0000244|PDB:4K81}.
FT   HELIX       195    198       {ECO:0000244|PDB:4K81}.
FT   TURN        201    203       {ECO:0000244|PDB:4K81}.
FT   TURN        206    208       {ECO:0000244|PDB:4K81}.
FT   HELIX       221    229       {ECO:0000244|PDB:4K81}.
FT   STRAND      236    244       {ECO:0000244|PDB:4K81}.
FT   STRAND      251    259       {ECO:0000244|PDB:4K81}.
FT   STRAND      262    268       {ECO:0000244|PDB:4K81}.
FT   TURN        274    276       {ECO:0000244|PDB:4K81}.
FT   STRAND      277    281       {ECO:0000244|PDB:4K81}.
FT   STRAND      283    291       {ECO:0000244|PDB:4K81}.
FT   TURN        297    299       {ECO:0000244|PDB:4K81}.
FT   STRAND      301    303       {ECO:0000244|PDB:4K81}.
FT   STRAND      305    310       {ECO:0000244|PDB:4K81}.
FT   STRAND      312    315       {ECO:0000244|PDB:4K81}.
FT   STRAND      320    323       {ECO:0000244|PDB:4K81}.
FT   HELIX       327    342       {ECO:0000244|PDB:4K81}.
FT   HELIX       344    351       {ECO:0000244|PDB:4K81}.
FT   STRAND      377    380       {ECO:0000244|PDB:2AUH}.
FT   STRAND      382    385       {ECO:0000244|PDB:2AUH}.
FT   HELIX       392    407       {ECO:0000244|PDB:2AUH}.
FT   HELIX       434    436       {ECO:0000244|PDB:2AUG}.
FT   HELIX       446    454       {ECO:0000244|PDB:2AUG}.
FT   TURN        455    457       {ECO:0000244|PDB:2AUG}.
FT   STRAND      462    467       {ECO:0000244|PDB:2AUG}.
FT   STRAND      469    472       {ECO:0000244|PDB:2AUG}.
FT   STRAND      475    481       {ECO:0000244|PDB:2AUG}.
FT   STRAND      484    495       {ECO:0000244|PDB:2AUG}.
FT   STRAND      498    504       {ECO:0000244|PDB:2AUG}.
FT   STRAND      510    512       {ECO:0000244|PDB:2AUG}.
FT   HELIX       513    520       {ECO:0000244|PDB:2AUG}.
FT   STRAND      527    529       {ECO:0000244|PDB:2AUG}.
SQ   SEQUENCE   540 AA;  60988 MW;  00472988650F7C6C CRC64;
     MTTSLQDGQS AASRAAARDS PLAAQVCGAA QGRGDAHDLA PAPWLHARAL LPLPDGTRGC
     AADRRKKKDL DVPEMPSIPN PFPELCCSPF TSVLSADLFP KANSRKKQVI KVYSEDETSR
     ALDVPSDITA RDVCQLLILK NHYIDDHSWT LFEHLPHIGV ERTIEDHELV IEVLSNWGIE
     EENKLYFRKN YAKYEFFKNP MYFFPEHMVS FATETNGEIS PTQILQMFLS SSTYPEIHGF
     LHAKEQGKKS WKKIYFFLRR SGLYFSTKGT SKEPRHLQFF SEFGNSDIYV SLAGKKKHGA
     PTNYGFCFKP NKAGGPRDLK MLCAEEEQSR TCWVTAIRLL KYGMQLYQNY MHPYQGRSGC
     SSQSISPMRS ISENSLVAMD FSGQKSRVIE NPTEALSVAV EEGLAWRKKG CLRLGTHGSP
     TASSQSSATN MAIHRSQPWF HHKISRDEAQ RLIIQQGLVD GVFLVRDSQS NPKTFVLSMS
     HGQKIKHFQI IPVEDDGEMF HTLDDGHTRF TDLIQLVEFY QLNKGVLPCK LKHYCARIAL
//
